Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03875287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started2019-04-17
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Sep 2, 2026 → Mar 2, 2027
See other at-risk trials from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Amendment history

2026-09-04
Study Status v16
Primary completion pushed: 2026-09-02 → 2027-03-02
Completion pushed: 2027-07-01 → 2027-09-01
2026-01-08
Recruiting→Active, Not Recruiting Study Status, Sponsor/Collaborators, Contacts/Locations v15
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2026-01-02→2026-09-02
Completion date2026-12-01→2027-07-01
Study sitesdetails revised at 2 of 2 sites
Collaborators1 to 2 entries
Stand Up To Cancer
2025-02-27
Active, Not Recruiting→Recruiting Study Status, Study Description, Study Design, Arms and Interventions, Contacts/Locations v14
Trial statusActive, Not Recruiting→Recruiting
Primary completion date2025-06-02→2026-01-02
Completion date2025-12-01→2026-12-01
Enrollment target29→35
Study sitesdetails revised at 2 of 2 sites
2024-12-11
Study Status v13
Primary completion date2024-01-02→2025-06-02
Completion date2024-12→2025-12-01
2024-01-08
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v12
Trial statusRecruiting→Active, Not Recruiting
Primary completion dateestimated 2023-12→confirmed 2024-01-02
Completion date2023-12→2024-12
Enrollment targetestimated 30→confirmed 29
Study sitesdetails revised at 2 of 2 sites
Show 11 earlier versions
2023-06-07
Study Status v11
Primary completion date2023-06→2023-12
Completion date2023-06→2023-12
2023-01-04
Study Status v10
Primary completion date2023-01→2023-06
Completion date2023-01→2023-06
2022-10-31
Study Status v9
Re-verified, no change to tracked fields
2021-11-18
Study Status v8
Primary completion date2022-01→2023-01
Completion date2022-01→2023-01
2021-08-18
Study Status, Study Design v7
Re-verified, no change to tracked fields
2021-03-10
Study Status, Arms and Interventions v6
Primary completion date2021-08→2022-01
Completion date2021-08→2022-01
2020-07-22
Study Identification, Study Status, Contacts/Locations v5
Primary completion date2020-08→2021-08
Completion date2020-08→2021-08
Study sites1→2
Study title-7 characters
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors
2019-12-13
Study Status, Contacts/Locations v4
Re-verified, no change to tracked fields
2019-06-11
Study Identification, Study Status v3
Start dateestimated 2019-05→confirmed 2019-04-17
2019-04-16
Not Yet Recruiting→Recruiting Study Status, Arms and Interventions, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2019-04-03
Study Status v1
Start date2019-03→2019-05
2019-03-13
Original filing
This is a phase 1 study of the combination of cedazuridine with decitabine in patients with solid tumors. At least 6 patients will be enrolled per treatment level to assess optimal hypomethylation and toxicity (up to 35 patients total).
Trial Details
NCT Number NCT03875287
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Astex Pharmaceuticals, Inc., Stand Up To Cancer
Conditions Solid Tumor
Enrollment 35 participants
Start Date 2019-04-17
Primary Completion 2027-03-02 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-08